Life Science Lending
The MidCap Financial Life Science Lending team has extensive experience financing venture backed and micro/small cap life science companies. We provide capital to development stage and early commercial stage biotech, specialty pharmaceutical, medical device, and diagnostics companies. Our capital serves as an attractive, minimally dilutive alternative to equity for financing product acquisitions, enhancing a product launch, or advancing development stage programs. We specialize in senior-secured term loans, but can also provide borrowing base-driven lines of credit for commercial stage companies.
The MidCap Financial Technology Lending team is focused on providing capital to private and public, commercial stage companies in the enterprise software, networking, internet and hardware industries. Our capital, structured as term loans and/or borrowing base-driven working capital lines of credit, supports sales & marketing growth, product expansion, financing working capital, acquisition financing and liquidity ahead of an IPO.
MidCap Financial Services, LLC*
President of Specialty Lending
email@example.com • 301-841-6437
William Gould is a co-founder of MidCap Financial and President of Asset Based and Life Sciences Lending. Prior to joining MidCap Financial, Mr. Gould created and ran the life sciences venture finance practice for Merrill Lynch Capital Healthcare Finance. Mr. Gould also served as a Team Leader responsible for underwriting asset based and specialty real estate loans at Merrill Lynch Capital. From 2001 to 2003, Mr. Gould was a Vice President at GE Capital’s Healthcare Commercial Finance business unit where he led the asset based underwriting group. Mr. Gould also spent four years in the corporate and securities group of the law firm of Hogan and Hartson. Mr. Gould holds a B.A. in Philosophy from Haverford College and a J.D. from the University of Virginia School of Law.
Managing Director & Head of Life Sciences Finance
firstname.lastname@example.org • 415-992-2564
James Taylor is the Managing Director & Head of Life Sciences Finance. Prior to joining MidCap Financial, Mr. Taylor was the head of Silicon Valley Bank’s San Francisco lending team specializing in loans to biotech, medical devices and diagnostics companies. In this capacity, Mr. Taylor was responsible for expanding the Bank’s venture debt portfolio and servicing over 150 client relationships. Prior to joining Silicon Valley Bank, Mr. Taylor was a director of business development for the Export – Import Bank in Washington DC, responsible for business development in Virginia, Maryland, North Carolina and South Carolina. Mr. Taylor graduated from Hamilton College in Clinton, NY with a double major in history and French. In his spare time, James is an avid backcountry fly-fisherman and skier.
Managing Director & Head of Technology Venture Finance
MMarziani@midcapfinancial.com • 312-488-4537
Michael Marziani is the Managing Director & Head of Technology Venture Finance. Prior to joining MidCap Financial in 2018, Mr. Marziani was Managing Director and Co-Head of the Venture Finance Group at Ares Management, where he was for 6 years. Previously, Mr. Marziani was a Managing Director and Co-Founder of BlueCrest Capital’s Venture Finance Group. Prior to joining BlueCrest, Mr. Marziani spent 4 years with GE Capital’s Technology Finance Group as Senior Vice President after GE’s acquisition of Heller Financial, where he served in 3 business units over 10 years. Mr. Marziani holds a B.S. from Fairfield University in Finance and an M.B.A. from the Northwestern University Kellogg School.
email@example.com • 312-234-0297
Colleen Kovas is an underwriter in MidCap Financial’s Life Sciences Lending group. Prior to joining MidCap Financial, Ms. Kovas was the Director of Portfolio Management at BlueCrest Capital Finance. Prior to that, Ms. Kovas was a member of the life sciences venture finance practice at Merrill Lynch Capital. Ms. Kovas began her career in corporate and financial public relations. Ms. Kovas holds a B.A., magna cum laude, in Government & International Studies from the University of Notre Dame.
firstname.lastname@example.org • 240-383-3120
Ross Hartman is a Director in MidCap Financial’s Life Science Lending group. Mr. Hartman has nearly a decade of experience providing debt financing to public and private companies. Prior to joining MidCap Financial, Mr. Hartman was a Senior Director at Oxford Finance where he was responsible for underwriting and portfolio management of life science venture loans. Prior to Oxford, Mr. Hartman was an Associate at MCG Capital, a middle market lender. Mr. Hartman holds a B.S. in Finance, summa cum laude, from Virginia Tech.
email@example.com • 240-383-1606
Nathan Rothschild is an underwriter in MidCap Financial’s Life Science and Asset Based Lending groups where he is responsible for structuring and executing senior financings. Mr. Rothschild has held various roles at MidCap Financial since 2012. He earned his Masters in Finance from the Owen Graduate School of Management at Vanderbilt University and a B.A. in Economics and Political Science, summa cum laude, from Vanderbilt University. He is a CFA charterholder.
firstname.lastname@example.org • 312-488-4526
Michael Guess joined MidCap Financial in 2014 and is a Director in the Life Sciences and Technology Lending group. He is responsible for originating, underwriting, and executing investments in public and venture-backed life sciences and technology companies. Prior to joining MidCap Financial, Michael was a member of KPMG’s Management Consulting practice where he advised life sciences companies on strategic and transformation initiatives. Mr. Guess holds a B.S. in Finance from the University of Illinois at Urbana-Champaign.
Josh Groman, Ph.D.
Deputy Chief Investment Officer
email@example.com • 301-841-6438
Josh Groman is currently Deputy Chief Investment Officer. Prior to joining MidCap Financial, Dr. Groman was head of underwriting for life science transactions at Merrill Lynch Capital Healthcare Finance. From 2004 to 2007, he served as an Engagement Manager in the life sciences consulting practice at Leerink Swann & Company where he advised biotech, pharmaceutical and device manufacturers on product strategy, business development and M&A due diligence. Dr. Groman holds a Ph.D. in Human Genetics and Molecular Biology from the Johns Hopkins School of Medicine and has published 11 research articles in leading scientific and medical journals. He also holds a B.S. from the State University of New York/Syracuse University and an M.S. in Biology from Vanderbilt University.
* See "Firm Overview" page for information on MidCap Financial's relationship with MidCap Financial Services, LLC and Apollo Capital Management, L.P.